Article Text

Download PDFPDF
Observational study
US counties with higher rates of breast cancer screening have higher rates of incidence with no concomitant decrease in breast cancer mortality suggesting overdiagnosis
  1. Rebecca A Hubbard
  1. Department of Biostatistics & Epidemiology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
  1. Correspondence to : Dr Rebecca A Hubbard, Department of Biostatistics & Epidemiology, University of Pennsylvania, 423 Guardian Dr, 604 Blockley Hall, Philadelphia, PA 19104 USA; rhubb{at}upenn.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: .

Context

The goal of screening mammography is to decrease breast cancer mortality by diagnosing tumours at an earlier, more treatable stage. Meta-analyses of randomised clinical trials have estimated that breast cancer screening results in approximately a 20% decrease in breast cancer mortality.1 However, breast cancer incidence and treatment, as well as performance of screening mammography, have evolved since the conclusion of most of these clinical trials and it is unclear whether screening in the modern era confers the same benefit. Moreover, substantial uncertainty still exists regarding the extent of over diagnosis, the diagnosis of tumours that would not have become clinically apparent within a woman's lifetime in the absence of …

View Full Text

Footnotes

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.